| PPY988 / Novartis |
2020-003987-22: Study to evaluate the long term safety of GT005 in participants having macular degeneration that led to geographic atrophy in their eyes and that have been previously treated in a prior Gyroscope study using the same product. |
|
|
| Ongoing | 2 | 200 | Europe | GT005, Suspension for injection | Gyroscope Therapeutics Ltd., Gyroscope Therapeutics Ltd. | Geographic atrophy (GA) secondary to age-related macular degeneration (AMD) in participants already treated with GT005 in the GT005-02 (EXPLORE) and GT005-03 (HORIZON) antecedent studies., Geographic atrophy (GA) secondary to age-related macular degeneration (AMD), a progressive disease that results in a blurred area or blank spot in the centre of vision, and very common in elderly., Diseases [C] - Eye Diseases [C11] | | | | |
2019-003421-22: A study to test the safety and effect of a treatment for people with sight loss due to dry Age-related Macular Degeneration |
|
|
| Not yet recruiting | 2 | 202 | Europe | Recombinant, non-replicating AAV2 expressing human CFI, GT005, Suspension for injection | Gyroscope Therapeutics, Gyroscope Therapeutics | Age-related Macular Degeneration (AMD) presents as a progressive loss of vision in the centre of the retina (the macula) resulting in a blurred area or blank spot in the centre of vision. The primary clinical characteristic of late stage AMD is atrophy of the Retinal PigmentEpithelium, known as macular atrophy due to AMD, which leads to the gradual degeneration of nearby photoreceptors, resulting in thinning of the retina and a progressive visual impairment., Age-related Macular Degeneration (AMD) presents as a progressive loss of vision in the centre of the retina (the macula) resulting in a blurred area or blank spot in the centre of vision., Diseases [C] - Eye Diseases [C11] | | | | |
| Terminated | 2 | 98 | Europe, US, RoW | GT005; Low Dose, GT005; High Dose | Gyroscope Therapeutics Limited, Novartis Pharmaceuticals | Dry Age-related Macular Degeneration | 04/24 | 04/24 | | |
| Terminated | 2 | 255 | Europe, US, RoW | GT005: Medium Dose, GT005: High Dose | Gyroscope Therapeutics Limited, Novartis Pharmaceuticals | Dry Age-related Macular Degeneration | 06/24 | 06/24 | | |
2020-002431-30: A study to test the safety and effect of a treatment for people with sight loss due to dry Age-related Macular Degeneration |
|
|
| Not yet recruiting | 2 | 250 | Europe | Recombinant, non-replicating AAV2 expressing human CFI, GT005, Suspension for injection | Gyroscope Therapeutics, Gyroscope Therapeutics | Age-related Macular Degeneration (AMD) presents as a progressive loss of vision in the centre of the retina (the macula) resulting in a blurred area or blank spot in the centre of vision. The primary clinical characteristic of late stage AMD is atrophy of the Retinal Pigment Epithelium, known as macular atrophy due to AMD, which leads to the gradual degeneration of nearby photoreceptors, resulting in thinning of the retina and a progressive visual impairment., Age-related Macular Degeneration (AMD) presents as a progressive loss of vision in the centre of the retina (the macula) resulting in a blurred area or blank spot in the centre of vision., Diseases [C] - Eye Diseases [C11] | | | | |
ORACLE, NCT05481827 / 2020-003987-22: A Long-term Follow-up Study to Evaluate the Safety of GT005 in Participants With Geographic Atrophy Secondary to Age-related Macular Degeneration Treated in a Gyroscope-sponsored Antecedent Study |
|
|
| Enrolling by invitation | 2 | 225 | Europe, US, RoW | GT005 | Gyroscope Therapeutics Limited, Novartis Pharmaceuticals | Age Related Macular Degeneration (AMD) | 06/28 | 06/28 | | |
2017-003712-39: A study to test the safety and effect of a new treatment for people with sight loss due to dry Age-related Macular Degeneration |
|
|
| Not yet recruiting | 1/2 | 30 | Europe | GT005, GT005, Suspension for injection | Gyroscope Therapeutics, Gyroscope Therapeutics | Age-related Macular Degeneration (AMD) presents as a progressive loss of vision in the centre of the retina (the macula) resulting in a blurred area or blank spot in the centre of vision. The primary clinical characteristic of late stage AMD is atrophy of the Retinal Pigment Epithelium, known as macular atrophy due to AMD, which leads to the gradual degeneration of nearby photoreceptors, resulting in thinning of the retina and a progressive visual impairment., Age-related Macular Degeneration (AMD) presents as a progressive loss of vision in the centre of the retina (the macula) resulting in a blurred area or blank spot in the centre of vision., Diseases [C] - Eye Diseases [C11] | | | | |
NCT03846193: FOCUS: A Phase I/II First in Human Study to Evaluate the Safety and Efficacy of GT005 Administered in Subjects With Dry AMD |
|
|
| Terminated | 1/2 | 56 | Europe, US | GT005, GT005/ Device: Orbit™ Subretinal Delivery System | Gyroscope Therapeutics Limited, Novartis Pharmaceuticals | Dry Age-related Macular Degeneration, Macular Degeneration, Retinal Disease, Eye Diseases, Retinal Degeneration, Geographic Atrophy, Macular Atrophy | 06/24 | 06/24 | | |
